<p>Two Year Visual Acuity and Structural Outcomes in Patients with Diabetic Macular Oedema Treated with Intravitreal Aflibercept – A Retrospective Cohort Study</p>

Christoph Kern, Johannes Schiefelbein, Dun Jack Fu, Benedikt Schworm, Dawn A. Sim, Tina Herold, Siegfried Priglinger, Karsten KortuemClinical 2020 · DOI

Abstract

This study demonstrates that treating DME with intravitreal aflibercept yields positive functional and structural outcomes over a two-year period. However, we observed fewer injection numbers, along with inferior VA and structural outcomes than has been reported in randomized clinical trials. Our results show similar results as in patients treated with ranibizumab due to DME in real-life settings.
BibTeX
@inproceedings{kern2020lt,
  author = {Christoph Kern and Johannes Schiefelbein and Dun Jack Fu and Benedikt Schworm and Dawn A. Sim and Tina Herold and Siegfried Priglinger and Karsten Kortuem},
  title = {{\<p\>Two Year Visual Acuity and Structural Outcomes in Patients with Diabetic Macular Oedema Treated with Intravitreal Aflibercept – A Retrospective Cohort Study\</p\>}},
  booktitle = {Clinical},
  year = {2020},
  doi = {10.2147/opth.s237586},
}

Loading related content...

Figure